L

Lunit Inc
KOSDAQ:328130

Watchlist Manager
Lunit Inc
KOSDAQ:328130
Watchlist
Price: 37 750 KRW -3.82%
Market Cap: 1.1T KRW

Lunit Inc's latest stock split occurred on Nov 9, 2023

The company executed a 2-for-1 stock split, meaning that for every share held, investors received 2 new shares.

Before the split, Lunit Inc traded at 170500 per share. Afterward, the share price was about 90200.

The adjusted shares began trading on Nov 9, 2023. This was Lunit Inc's 2nd stock split, following the previous one in Sep 22, 2023.

Last Splits:
Nov 9, 2023
2-for-1
Sep 22, 2023
1495-for-1398
Pre-Split Price
85 250 170 500
Post-Split Price
90 200
Before
After
Last Splits:
Nov 9, 2023
2-for-1
Sep 22, 2023
1495-for-1398

Lunit Inc
Stock Splits History

Lunit Inc Stock Splits Timeline
Nov 9, 2023
Nov 9, 2023
Split 2-for-1
x2
Pre-Split Price
85 250 170 500
Post-Split Price
90 200
Before
After
Sep 22, 2023
Sep 22, 2023
Split 1495-for-1398
x1.0693848354793
Pre-Split Price
100 291.3053 214 499.8776
Post-Split Price
100 500
Before
After

Global
Stock Splits Monitor

Date Company Split Pre-Split Price Post-Split Price
Dec 29, 2025
Ise Chemicals Corp
OTC:ICHMF
10-for-1
x10
32.808 32.808 USD N/A
Dec 29, 2025
Bridgestone Corp
OTC:BRDCF
2-for-1
x2
47.5 47.5 USD N/A
Dec 29, 2025
Ibiden Co Ltd
OTC:IBIDF
2-for-1
x2
81 81 USD N/A
Dec 29, 2025
Itochu Corp
OTC:ITOCF
5-for-1
x5
60.6 60.6 USD N/A
Dec 29, 2025
Sumitomo Realty & Development Co Ltd
OTC:SURDF
2-for-1
x2
47.945 47.945 USD N/A
Load More

Lunit Inc
Glance View

Market Cap
1.1T KRW
Industry
Health Care

Lunit Inc., founded in South Korea, stands as a pioneering force in the application of artificial intelligence within the realm of medical technology. As a company at the intersection of healthcare and cutting-edge AI, Lunit crafts advanced solutions that enhance the diagnostic processes in radiology and oncology. The company's name, derived from "learning unit," underscores its mission to employ deep learning as a core component in transforming medical diagnostics. At the heart of Lunit’s operations are their flagship products, Lunit INSIGHT and Lunit SCOPE, which are designed to empower physicians by providing highly accurate diagnostic readings and treatment predictions. With this technology, Lunit aims to reduce diagnostic errors and improve the efficiency of medical imaging analysis, ultimately enhancing patient treatment outcomes. Lunit generates revenue through strategic partnerships and sales of their AI software solutions to hospitals and healthcare providers globally. The company's business model involves not only licensing its AI technologies but also integrating them with existing medical imaging equipment, thus enhancing the value derived from traditional diagnostic tools. By collaborating with prominent medical device manufacturers and healthcare institutions, Lunit ensures both the scalability and adaptability of its products in diverse clinical settings. Additionally, they actively engage in research collaborations and pilot programs to further their technological advancements and expand their market presence. Through these endeavors, Lunit is steadily carving out a crucial role in the healthcare sector by offering AI-driven solutions that promise to revolutionize patient care.

Intrinsic Value
14 867.12 KRW
Overvaluation 61%
Intrinsic Value
Price
L
Back to Top